Opus Point Partners Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Opus Point Partners Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-308,569	Closed	-$1.14M	–	49
2018 Q3	$1.14M	Buy	+308,569	New	+$920K	2.71%	14
2016 Q2	–	Sell	-99,000	Closed	-$764K	–	56
2016 Q1	$764K	Sell	99,000 -1,000	-1%	-$7.32K	0.59%	37
2015 Q4	$1.08M	Sell	100,000 -6,104	-6%	-$55.5K	0.71%	38
2015 Q3	$733K	Buy	106,104 +39,400	+59%	+$321K	0.4%	36
2015 Q2	$591K	Hold	66,704	–	–	0.47%	46
2015 Q1	$658K	Buy	66,704 +16,704	+33%	+$209K	0.55%	48
2014 Q4	$613K	Buy	+50,000	New	+$611K	0.61%	44

Other funds holding ACHN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Opus Point Partners Management's ACHN Position: Q4 2018 in Review

Opus Point Partners Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 308,569 shares — an estimated $1.14M sold.

Opus Point Partners Management first reported a position in ACHN in Q4 2014 and held it in 7 quarters. The position peaked at $1.14M in Q3 2018. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

Opus Point Partners Management reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Opus Point Partners Management sold 308,569 Achillion Pharmaceuticals shares in Q4 2018, an estimated $1.14M.
Opus Point Partners Management first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 7 quarters.
Opus Point Partners Management's Achillion Pharmaceuticals position peaked at $1.14M in Q3 2018.
121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on Opus Point Partners Management's 13F filing for Q4 2018, filed 14 Feb 2019.